Hair Loss Labs and Next Steps: The Diagnostic Workup You Actually Need

Why Lab Testing Is Non-Negotiable for Hair Loss

Diagnosing hair loss by visual inspection alone misses reversible causes in roughly one-third of patients. A 2019 systematic review in the Journal of the American Academy of Dermatology found that iron deficiency without anemia contributed to hair shedding in 23% of premenopausal women presenting with diffuse hair loss. Without ferritin testing, these patients often receive minoxidil prescriptions that address the symptom but not the root driver.

The logic is straightforward: hair follicles are metabolically expensive tissue. They cycle through anagen (growth), catagen (transition), and telogen (rest) phases over 2-7 years. Any systemic disruption (nutrient depletion, hormonal shift, autoimmune activation, metabolic stress) can prematurely shift follicles into telogen. The shed appears 2-4 months after the insult. Blood tests taken at presentation capture the biochemical environment that triggered the shift weeks earlier.

Pattern matters too. Diffuse thinning across the entire scalp suggests systemic causes (thyroid, iron, zinc). Bitemporal recession or vertex thinning in men points toward dihydrotestosterone (DHT)-mediated miniaturization. A widening part in women with preserved frontal hairline suggests female-pattern hair loss. Patchy, well-demarcated loss raises suspicion for alopecia areata. Each pattern narrows the lab panel.

The Core Blood Panel: What to Order First

The initial workup should include seven to ten tests that cover the most common reversible causes. This is not a fishing expedition. Each test maps to a specific mechanism.

Ferritin is the single most underordered test in hair loss workups. The British Journal of Dermatology published data showing that women with unexplained chronic telogen effluvium had mean ferritin levels of 27.3 ng/mL versus 59.5 ng/mL in age-matched controls. Many labs flag ferritin as "normal" above 12 ng/mL, but hair growth appears to require levels above 40-70 ng/mL. Request the actual number, not just the normal/abnormal flag.

TSH and free T4 catch both hypo- and hyperthyroidism. Subclinical hypothyroidism (TSH 4.5-10 mIU/L with normal free T4) can trigger diffuse shedding months before fatigue or weight gain appear. The American Thyroid Association guidelines note that hair loss is among the earliest presenting symptoms of thyroid dysfunction.

Complete blood count (CBC) screens for anemia, which compounds iron-deficiency effects on hair cycling.

Vitamin D (25-hydroxyvitamin D) levels below 30 ng/mL have been associated with telogen effluvium and alopecia areata in a meta-analysis of 14 observational studies published in the International Journal of Dermatology.

Zinc deficiency, though less common, directly impairs keratinocyte proliferation. Serum zinc below 70 mcg/dL warrants supplementation.

DHEA-S and total/free testosterone are indicated for women with signs of hyperandrogenism (acne, hirsutism, irregular cycles) and for men under 30 with aggressive vertex thinning. In women, a free testosterone above 6.4 pg/mL or DHEA-S above 400 mcg/dL should prompt evaluation for polycystic ovary syndrome or adrenal hyperplasia.

Second-Tier Labs: When the Initial Panel Is Normal

If the core panel returns unremarkable and shedding persists beyond 6 months, expand the investigation.

Anti-nuclear antibody (ANA) and anti-thyroid peroxidase (anti-TPO) screen for autoimmune conditions. Alopecia areata occurs in isolation, but its presence increases the odds of concurrent Hashimoto's thyroiditis by 8-fold according to a 2015 cohort study in JAMA Dermatology (N=4,399).

Prolactin elevation can suppress gonadotropins and trigger diffuse thinning. It is particularly relevant in women taking SSRIs or antipsychotics.

Insulin and hemoglobin A1c identify metabolic syndrome, which drives hyperandrogenism through increased ovarian androgen production and decreased sex hormone-binding globulin (SHBG). SHBG below 30 nmol/L effectively amplifies free androgen activity at the follicle.

Scalp biopsy (two 4mm punch biopsies, one horizontal and one vertical section) becomes the gold standard when trichoscopy and labs fail to clarify the diagnosis. It distinguishes scarring from non-scarring alopecia, confirms lichen planopilaris or frontal fibrosing alopecia, and quantifies the terminal-to-vellus hair ratio.

The Physical Examination: What Your Clinician Should Be Doing

A thorough scalp exam takes 5-10 minutes and provides diagnostic information that bloodwork cannot.

The pull test involves grasping 60 hairs between thumb and forefinger, applying gentle traction, and counting extracted hairs. More than 6 hairs (10%) constitutes a positive pull test indicating active shedding. This test should be performed in at least three scalp regions (frontal, parietal, occipital).

Trichoscopy (dermoscopy of the scalp at 10-70x magnification) identifies miniaturized hairs, yellow dots (empty follicles), black dots (broken hairs), exclamation-mark hairs (pathognomonic for alopecia areata), and perifollicular scaling. A 2020 study in the Indian Journal of Dermatology reported 94.2% sensitivity and 97.1% specificity for trichoscopy in differentiating androgenetic alopecia from chronic telogen effluvium.

Hair density mapping involves parting the hair at standardized locations and photographing under consistent lighting. This creates a baseline for tracking treatment response over 6-12 months.

The wash test, where patients collect all hairs lost during a standardized shampoo after 5 days of no washing, provides a quantitative shedding count. Counts above 100 hairs indicate abnormal telogen release.

Androgenetic Alopecia: The Diagnosis and What Follows

Androgenetic alopecia (AGA) accounts for 95% of hair loss in men and roughly 40% of hair loss in women over 50. The diagnosis is primarily clinical.

In men, the Hamilton-Norwood scale grades severity from stage I (minimal recession) through stage VII (complete vertex and frontal loss). The mechanism involves 5-alpha reductase conversion of testosterone to DHT, which binds androgen receptors on genetically susceptible follicles in the vertex and frontal scalp, triggering progressive miniaturization over successive hair cycles.

The Prostate Cancer Prevention Trial (N=18,882) demonstrated that finasteride 5mg reduced serum DHT by 70%. Hair-specific trials at the 1mg dose (the Kaufman study, N=1,553) showed that finasteride 1mg increased hair count by a mean of 107 hairs per cm² at 2 years versus continued loss in the placebo group.

For women, the Ludwig scale classifies diffuse thinning across the crown. Because finasteride is teratogenic (FDA Category X), treatment options differ. Topical minoxidil 5% remains first-line. Spironolactone 100-200mg daily, used off-label, blocks androgen receptors at the follicle. A randomized trial published in the British Journal of Dermatology (N=100) found spironolactone 200mg non-inferior to cyproterone acetate for female-pattern hair loss at 12 months.

Dr. Wilma Bergfeld, former president of the American Academy of Dermatology, has stated: "The key to managing androgenetic alopecia is early intervention. Once a follicle has been miniaturized through multiple cycles, recovery becomes progressively less likely."

Telogen Effluvium: Identifying the Trigger

Telogen effluvium (TE) is the most common cause of acute diffuse hair shedding. The hallmark is onset 2-4 months after a precipitating event. Labs may be normal if the trigger was transient (surgery, high fever, crash diet, emotional trauma, medication change).

Common pharmacologic triggers include:

• Retinoids (isotretinoin, acitretin)
• Anticoagulants (heparin, warfarin)
• Beta-blockers (propranolol, metoprolol)
• Antithyroid drugs (methimazole)
• Anticonvulsants (valproic acid)
• Oral contraceptive discontinuation

The natural history of acute TE is self-resolution within 6-9 months once the trigger is removed. No pharmacologic treatment accelerates regrowth in acute TE beyond addressing identified deficiencies.

Chronic TE (persisting beyond 6 months without an identifiable trigger) is a distinct entity first described by Whiting in 1996. It affects women almost exclusively, tends to fluctuate in severity, and may persist for years. The prognosis is good in that complete baldness does not occur, but patients require reassurance supported by quantitative hair counts showing stable density.

Alopecia Areata: The Autoimmune Pattern

Patchy, round areas of complete hair loss with preserved follicular ostia define alopecia areata (AA). The pathophysiology involves CD8+ T-lymphocyte attack on anagen-phase follicles. Lifetime prevalence is approximately 2%, with peak onset in the second and third decades.

Lab workup for suspected AA should include TSH, anti-TPO, ANA, and CBC. The JAK inhibitor baricitinib (Olumiant) received FDA approval in June 2022 for severe AA based on the BRAVE-AA1 and BRAVE-AA2 trials. In BRAVE-AA1 (N=654), baricitinib 4mg produced a SALT score of 20 or less (80%+ scalp coverage) in 38.8% of patients at 36 weeks versus 6.2% for placebo.

Ritlecitinib (Litfulo), a JAK3/TEC inhibitor, gained FDA approval in June 2023 for patients 12 years and older. The ALLEGRO-2b/3 trial (N=718) demonstrated that 50mg daily achieved SALT-20 response in 23% at 24 weeks.

Nutritional Optimization: Evidence-Based Targets

Correcting identified deficiencies produces measurable regrowth in responsive patients within 3-6 months.

Iron repletion: Target ferritin above 70 ng/mL. Ferrous sulfate 325mg (65mg elemental iron) taken every other day optimizes absorption based on hepcidin cycling research published in Blood. Take with vitamin C 200mg. Avoid concurrent calcium, coffee, or tea. Recheck ferritin at 3 months.

Vitamin D: For levels below 30 ng/mL, 5 to 000 IU daily for 8-12 weeks, then 2 to 000 IU maintenance. Target 40-60 ng/mL. The Endocrine Society guidelines support aggressive repletion for documented deficiency.

Zinc: 30-50mg elemental zinc daily for 3 months if serum zinc is low. Monitor copper at 3 months as zinc competes for absorption.

Biotin: Despite widespread marketing, a 2017 systematic review in Skin Appendage Disorders found no evidence supporting biotin supplementation for hair loss in the absence of documented biotin deficiency. Biotin supplementation does interfere with troponin and TSH immunoassays, potentially causing dangerous false results. Disclose biotin use before any lab draw.

When to Refer: Red Flags and Specialist Triggers

Primary care can manage straightforward TE and early AGA. Refer to dermatology for:

• Scarring alopecia (loss of follicular ostia on examination)
• Suspected alopecia areata affecting more than 25% of the scalp
• Female-pattern hair loss unresponsive to minoxidil at 6 months
• Uncertain diagnosis after labs and trichoscopy
• Frontal fibrosing alopecia (progressive hairline recession with eyebrow loss in postmenopausal women)

Refer to endocrinology for:

• DHEA-S above 700 mcg/dL (adrenal tumor screening)
• Virilization signs with elevated free testosterone
• Persistent TSH abnormalities requiring dose titration

Dr. Amy McMichael, professor of dermatology at Wake Forest School of Medicine, has noted: "The most common error in hair loss management is treating empirically without completing the diagnostic workup. A three-month delay for proper diagnosis saves years of ineffective treatment."

Building Your Treatment Timeline

Once labs return and pattern is classified, treatment follows a predictable structure.

Months 1-3: Address deficiencies (iron, D, zinc, thyroid). Initiate topical minoxidil 5% if AGA confirmed. Begin oral finasteride 1mg daily (men) or spironolactone 100mg daily (women with AGA) if indicated. Shedding may transiently increase during the first 4-8 weeks of minoxidil (a positive prognostic sign indicating follicle cycling).

Months 3-6: First follow-up labs (ferritin, TSH). Repeat standardized photography. Pull test should normalize by month 4-5 in TE. Hair count stabilization is the first goal; regrowth follows.

Months 6-12: Assess treatment response with comparative photography and patient-reported outcomes. If finasteride is inadequate, consider dutasteride 0.5mg (which inhibits both type I and type II 5-alpha reductase, reducing DHT by 90% versus 70% with finasteride). Dutasteride for AGA remains off-label in the United States but is approved in South Korea and Japan based on a phase III trial showing superiority over finasteride 1mg at 24 weeks (N=416).

Month 12+: Annual monitoring. Adjust doses. Consider adjunctive low-level laser therapy (LLLT) at 655nm. The HairMax LaserComb FDA clearance trial (N=128) demonstrated 20.9 additional hairs/cm² at 26 weeks in men with AGA. Platelet-rich plasma (PRP) injections every 3-4 months may add benefit, though the 2019 Cochrane review noted high heterogeneity and insufficient evidence to make definitive recommendations.

Baseline ferritin for women presenting with diffuse hair loss should be repleted above 70 ng/mL before concluding that iron is not contributory, regardless of whether hemoglobin is within normal range.